Temintas 5 mg/20 mg/100 mg/ 250mg Hard gelatin capsules
PDF Leaflet Revision Date: 08 October 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Indicated for glioblastoma multiforme, recurrent malignant glioma, and advanced metastatic malignant melanoma.
Dosage (summary)
75 mg/mu00b2 daily for 42 days with radiotherapy; then 150 mg/mu00b2 for 5 days in Cycle 1, escalating to 200 mg/mu00b2 in subsequent cycles.
Special Populations
- Elderly patients
- Paediatric patients
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; teratogenic effects possible.
Key Drug Interactions
- Increased myelosuppression with other myelosuppressive agents
- Decreased clearance with valproic acid
Contraindications
- Hypersensitivity to components
- Severe myelosuppression
- Pregnancy
- Lactation
Common side effects
- Nausea
- Vomiting
- Fatigue
- Neutropenia
- Thrombocytopenia
Counselling Points
- Take on an empty stomach
- Do not open or chew capsules
- Use effective contraception during treatment
Serious warnings
- Risk of Pneumocystis carinii pneumonia with concomitant radiotherapy
- Myelosuppression may occur
Important Disclaimer
The Temintas 5 mg/20 mg/100 mg/ 250mg Hard gelatin capsules professional information leaflet below is the property of Eurolab and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
